Abstract
This review paper discusses the central role of gamma-aminobutyric acid (GABA) in diverse physiological systems and functions and the therapeutic potential of the benzodiazepine antagonist flumazenil (Ro 15- 1788) for a wide range of disorders of the central nervous system (CNS). Our group and others have studied the potential of flumazenil as a treatment for benzodiazepine dependence. A small but growing body of research has indicated that flumazenil may also have clinical application in CNS disorders such as Parkinson’s disease, idiopathic hypersomnia and amyotrophic lateral sclerosis. Despite this body of research the therapeutic potential of flumazenil remains poorly understood and largely unrealized.
The purpose of this paper is not to provide an exhaustive review of all possible therapeutic applications for flumazenil but rather to stimulate research interest, and discussion of the exciting therapeutic potential of this drug for a range of chronic debilitating conditions.
Keywords: Amyotrophic lateral sclerosis, benzodiazepine, central nervous system, flumazenil, GABA, idiopathic hypersomnia, Parkinson’s disease.
Current Pharmaceutical Design
Title:Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Volume: 21 Issue: 23
Author(s): Gary Hulse, Erin Kelty, Sean Hood, Amanda Norman, Maria Rita Basso and Albert Stuart Reece
Affiliation:
Keywords: Amyotrophic lateral sclerosis, benzodiazepine, central nervous system, flumazenil, GABA, idiopathic hypersomnia, Parkinson’s disease.
Abstract: This review paper discusses the central role of gamma-aminobutyric acid (GABA) in diverse physiological systems and functions and the therapeutic potential of the benzodiazepine antagonist flumazenil (Ro 15- 1788) for a wide range of disorders of the central nervous system (CNS). Our group and others have studied the potential of flumazenil as a treatment for benzodiazepine dependence. A small but growing body of research has indicated that flumazenil may also have clinical application in CNS disorders such as Parkinson’s disease, idiopathic hypersomnia and amyotrophic lateral sclerosis. Despite this body of research the therapeutic potential of flumazenil remains poorly understood and largely unrealized.
The purpose of this paper is not to provide an exhaustive review of all possible therapeutic applications for flumazenil but rather to stimulate research interest, and discussion of the exciting therapeutic potential of this drug for a range of chronic debilitating conditions.
Export Options
About this article
Cite this article as:
Hulse Gary, Kelty Erin, Hood Sean, Norman Amanda, Basso Rita Maria and Reece Stuart Albert, Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619092720
DOI https://dx.doi.org/10.2174/1381612821666150619092720 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in the Applications of Palladium Complexes Bearing N-Heterocyclic Carbene Ligands
Current Organic Chemistry Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry BK Polyoma Virus Nephropathy in an Immunocompromised Host
New Emirates Medical Journal What they are, How they Work and Why they do What they do? The Story of SV40-derived Gene Therapy Vectors and What They Have to Offer
Current Gene Therapy Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Inhibiting Protein-Protein Interactions as an Emerging Paradigm for Drug Discovery
Mini-Reviews in Medicinal Chemistry Applications of the Rare Earth Elements in Cancer Imaging and Therapy
Current Nanoscience Streamlined In Vivo Selection and Screening of Human Prostate Carcinoma Avid Phage Particles for Development of Peptide Based In Vivo Tumor Imaging Agents
Combinatorial Chemistry & High Throughput Screening TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy
Current Cancer Drug Targets